A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)

• Clive Ballard ,

  *To whom correspondence should be addressed. E-mail: clive.ballard@kcl.ac.uk

  Affiliation Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom

  ⨯
• Marisa Margallo Lana,

  Affiliation Northgate Hospital, Morpeth, Northumberland, United Kingdom

  ⨯
• Megan Theodoulou,

  Affiliation Department of Psychiatry, University of Oxford, The Warneford Hospital, Oxford, United Kingdom

  ⨯
• Simon Douglas,

  Affiliation Department of Psychiatry, Newcastle University, Newcastle upon Tyne, United Kingdom

  ⨯
• Rupert McShane,

  Affiliation Oxfordshire and Buckinghamshire Mental Health NHS Trust and University of Oxford, Department of Psychiatry, Fulbrook Centre, Oxford, United Kingdom

  ⨯
• Robin Jacoby,

  Affiliation Department of Psychiatry, University of Oxford, The Warneford Hospital, Oxford, United Kingdom

  ⨯
• Katja Kossakowski,

  Affiliation Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom

  ⨯
• Ly-Mee Yu,

  Affiliation Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• Edmund Juszczak,

  Affiliation Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

  ⨯
• on behalf of the Investigators DART AD